25.98

7.94% 1.91

After Hours: 25.98

Aktis Oncology Inc (AKTS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Aktis Oncology Inc stock is traded at $25.98, with a volume of 774.24K. It is up +7.94% in the last 24 hours and up +8.75% over the past month. Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

Previous Close:

$24.07

Open:

$24.15

24h Volume:

774.24K

Relative Volume:

2.19

Market Cap:

$1.44B

Revenue:

$29.71M

Net Income/Loss:

$-69.15M

P/E Ratio:

-23.09

EPS:

-1.1251

Net Cash Flow:

$-52.28M

1W Performance:

+5.10%

1M Performance:

+8.75%

6M Performance:

+29.90%

1Y Performance:

+69,739%

1-Day Range:

$22.95

$26.31

1-Week Range:

$22.95

$26.31

52-Week Range:

$14.72

$34.19

Aktis Oncology Inc Stock (AKTS) Company Profile

Name

Aktis Oncology Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

978-237-4380

Address

17 DRYDOCK AVENUE, BOSTON, NC

Employee

Twitter

@akoustisinc

Next Earnings Date

2026-08-17

Latest SEC Filings

AKTS's Discussions on Twitter

Compare AKTS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKTS Aktis Oncology Inc	25.98	1.33B	29.71M	-69.15M	-52.28M	-1.1251
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Initiated	H.C. Wainwright	Buy
Feb-03-26	Initiated	BofA Securities	Buy
Feb-03-26	Initiated	JP Morgan	Overweight
Feb-03-26	Initiated	Leerink Partners	Outperform
Feb-03-26	Initiated	TD Cowen	Buy
Jan-04-24	Downgrade	Piper Sandler	Overweight → Neutral
Sep-06-23	Downgrade	B. Riley Securities	Buy → Neutral
Jan-24-23	Initiated	B. Riley Securities	Buy
Feb-02-21	Reiterated	Craig Hallum	Buy
Jan-15-21	Reiterated	Craig Hallum	Buy
Sep-18-19	Downgrade	Northland Capital	Outperform → Market Perform
Jul-10-19	Upgrade	Northland Capital	Market Perform → Outperform
May-13-19	Reiterated	Craig Hallum	Buy
Feb-05-19	Reiterated	Craig Hallum	Buy
Feb-05-19	Downgrade	Northland Capital	Outperform → Market Perform
Dec-18-18	Initiated	Craig Hallum	Buy
Nov-30-18	Initiated	Lake Street	Buy
Jun-22-18	Initiated	Loop Capital	Buy
Feb-09-18	Initiated	Drexel Hamilton	Buy

View All

Aktis Oncology Inc Stock (AKTS) Latest News

Aug 21, 2026

Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat

Aug 21, 2026

Aug 19, 2026

AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget

Aug 19, 2026

Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa

Aug 19, 2026

Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat

Aug 19, 2026

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance

Aug 19, 2026

Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com

Aug 19, 2026

BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada

Aug 19, 2026

AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus

Aug 19, 2026

Aug 18, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 18, 2026

Aug 17, 2026

Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn

Aug 17, 2026

Aug 15, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn

Aug 15, 2026

Aug 14, 2026

Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com

Aug 14, 2026

BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo

Aug 14, 2026

AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus

Aug 14, 2026

Aug 13, 2026

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com

Aug 13, 2026

Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade

Aug 13, 2026

Aktis: Q2 Earnings Snapshot - WKYC

Aug 13, 2026

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times

Aug 13, 2026

Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan

Aug 13, 2026

Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan

Aug 13, 2026

Aug 08, 2026

Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Pairs Trade - vinanet.vn

Aug 08, 2026

Aug 06, 2026

Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Aug 06, 2026

Aug 03, 2026

Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Stop Run - Vinanet

Aug 03, 2026

Aug 02, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesAnalyst Drop Coverage - vinanet.vn

Aug 02, 2026

Jul 31, 2026

AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Revenue Warning Signal - vinanet.vn

Jul 31, 2026

Jul 28, 2026

Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat

Jul 28, 2026

Jul 27, 2026

AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey

Jul 27, 2026

Jul 24, 2026

Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st

Jul 24, 2026

Jul 22, 2026

AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget

Jul 22, 2026

Aktis Oncology Inc : Leerink Partners Assumes - Moomoo

Jul 22, 2026

Aktis Oncology director Ken Herrmann sells $119,274 in stock By Investing.com - Investing.com Australia

Jul 22, 2026

Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat

Jul 22, 2026

Jul 21, 2026

Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria

Jul 21, 2026

Aktis Oncology (AKTS) director sells 4,856 shares after exercising options - Stock Titan

Jul 21, 2026

Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com

Jul 21, 2026

Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget

Jul 21, 2026

Jul 20, 2026

Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget

Jul 20, 2026

AKTS Pulls Back After Recent Gains: Key Levels to Watch for Aktis Oncology (AKTS)Volatility Skew - dars.gov.et

Jul 20, 2026